Human FasL, evolution and plasmin cleavage
A human-specific FasL substitution creates a proteolytic vulnerability in studied solid-tumor settings.
Research
12 projects
A macaque TIGIT shedding difference
A T119R sequence difference permits plasmin cleavage of macaque TIGIT in the tested systems.
The regulatory Fas epitope
Mapping a Fas/CD95 epitope clarifies antibody agonism and a CAR-T bystander response in ovarian cancer models.
FOLR1-anchored DR5 bispecific antibody
A dual-specificity antibody anchors to FOLR1 and activates DR5 in preclinical ovarian cancer systems.
DR5 agonism and PD-L1 immune evasion
DR5 agonist experiments reveal a PD-L1-associated response in several studied solid-tumor settings.
Surface charge and DR5 antibody response
A positively charged receptor patch influences the activity of tested clinical DR5 antibodies.
Engineered HCMV-derived DR5/CD155 biologic
A published UC invention proposes dual action on DR5 apoptosis and the CD155–TIGIT axis.
BPTI-derived plasmin-resistant peptide
A UC Davis disclosure describes a synthetic peptide designed to resist plasmin cleavage.
Tumor-directed Fas antibody formats
A UC Davis listing describes Fas epitope antibodies and bispecific formats designed for tumor selectivity.
TRIM37 in breast-cancer outcomes
Coauthored studies examine TRIM37-linked chemoresistance, metastasis and a population-associated variant.
X-chromosome reactivation in Rett research
A coauthored interdisciplinary study targets microRNA control of X inactivation in Rett models.
Furin disruption in SARS-CoV-2 models
A cell-based study examines furin targeting during the viral infection cycle.
No projects match those filters. Clear your search or choose another area.